Another vaccine manufacturing effort has kicked off in Africa, this time centered around access to low-cost measles and rubella shots.
The CDMO said today that it has finalized plans for a new 12,000-square-meter building to be constructed at the Bioscience Park in Leiden, the Netherlands. The company expects the manufacturing facility to be operational around the third quarter of 2024.
Batavia Biosciences has unveiled plans for the expansion of its headquarters and R&D capacities in the Netherlands by adding 22,500 square feet to its infrastructure. The expansion allows the company to increase its R&D activities for viral vector-based product development including Lentivirus, AAV, Adenovirus, and Measles virus vectors. In addition, the increased R&D infrastructure helps to meet increased global demand for vaccine development, be it live-attenuated, whole killed, vectored, or subunit vaccines. The expansion will be finalized by June 2023.
After successful completion, Batavia will continue to scale-up and optimize the process for commercial scale.
Privately held Batavia Biosciences said on Tuesday it is working with Swiss start-up Swiss Rockets AG on an investigational COVID-19 vaccine that both companies hope to begin testing in humans next year.
Leiden, 6 July 2021 – Today, Batavia Biosciences announces their collaboration with RocketVax, a subsidiary of Swiss Rockets AG developing vaccines based on breakthrough genetic engineering. Under the agreement, Batavia will develop the clinical process and deliver clinical product of RocketVax’s vaccine candidate against the SARS-CoV-2 virus.
KU Leuven, a research institution and one of the top 50 universities in the world, and Batavia Biosciences, a contract development and manufacturing organization focused on delivering sustainable manufacturing solutions in the field of vaccines and oncology, have partnered to develop a vector based COVID-19 vaccine candidate.
Batavia Biosciences, a biopharmaceutical contract development manufacturing organization, and Valneva Sweden AB, the Swedish subsidiary of Valneva SE, announced on June 15, 2020 that they have entered into a collaboration to accelerate market access of a low-cost inactivated polio vaccine (IPV).